A detailed history of China Universal Asset Management Co., Ltd. transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 10,931 shares of HRMY stock, worth $360,723. This represents 0.05% of its overall portfolio holdings.

Number of Shares
10,931
Previous 6,672 63.83%
Holding current value
$360,723
Previous $201,000 116.92%
% of portfolio
0.05%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$30.0 - $39.95 $127,770 - $170,147
4,259 Added 63.83%
10,931 $436,000
Q2 2024

Jul 19, 2024

SELL
$28.81 - $33.01 $121,607 - $139,335
-4,221 Reduced 38.75%
6,672 $201,000
Q1 2024

Apr 29, 2024

BUY
$29.93 - $35.06 $123,191 - $144,306
4,116 Added 60.73%
10,893 $366,000
Q4 2023

May 21, 2024

SELL
$19.2 - $33.78 $79,027 - $139,038
-4,116 Reduced 37.79%
6,777 $218,000
Q4 2023

Jan 23, 2024

BUY
$19.2 - $33.78 $100,684 - $177,142
5,244 Added 342.07%
6,777 $219,000
Q3 2023

May 21, 2024

BUY
$31.89 - $39.03 $23,853 - $29,194
748 Added 95.29%
1,533 $50,000
Q3 2023

Oct 30, 2023

BUY
$31.89 - $39.03 $23,853 - $29,194
748 Added 95.29%
1,533 $50,000
Q2 2023

May 21, 2024

SELL
$30.5 - $37.4 $671 - $822
-22 Reduced 2.73%
785 $27,000
Q2 2023

Jul 27, 2023

SELL
$30.5 - $37.4 $671 - $822
-22 Reduced 2.73%
785 $28,000
Q1 2023

May 21, 2024

BUY
$30.8 - $53.92 $6,283 - $10,999
204 Added 33.83%
807 $26,000
Q1 2023

Apr 27, 2023

BUY
$30.8 - $53.92 $6,283 - $10,999
204 Added 33.83%
807 $26,000
Q4 2022

May 21, 2024

SELL
$45.4 - $60.91 $467,166 - $626,763
-10,290 Reduced 94.46%
603 $33,000
Q4 2022

Jan 31, 2023

BUY
$45.4 - $60.91 $2,224 - $2,984
49 Added 8.84%
603 $33,000
Q3 2022

Oct 21, 2022

BUY
$42.06 - $55.45 $23,301 - $30,719
554 New
554 $25,000

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $1.95B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.